Lion Biotechnologies, Inc.’s (OTCQB: LBIO) share volume jolted upwards on May 1st, with 425,627 shares exchanging hands, almost four times higher than the three month average of 117,707 shares.
Since Lion Biotechnologies hasn’t issued any press releases since 2013 and there has been no news coverage of the company lately, it’s anybody’s guess has to why its stock volume and value have suddenly surged.
However, here is what we know about the company:
Lion Biotechnologies is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs). Our TIL technology, which was developed at National Cancer Institute and is currently in use at leading US cancer centers, has demonstrated robust efficacy in metastatic melanoma and is potentially applicable to all solid tumors. As we continue advancing our current clinical programs, we are also developing next-generation TILs and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost. With unique and versatile technology, promising clinical programs, strong intellectual property, high-profile collaborations and seasoned leadership, we believe Lion has the potential to create meaningful value for its stakeholders.
Lion Biotechnologies share price closed at $8.95, up 4% from its previous close of $8.60.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential like US Energy Initiative Corporation, Inc. had today, sign up here:
OncoSec Medical Incorporated’s (OTCQB: ONCS) share volume remained high, with 1,400,072 shares exchanging hands on May 1st. With a small increase of two cents from its previous close of $.73, OncoSec closed the day at $.75.
Earlier this week, OncoSec reported it would present at seven events in May promoting its ImmunoPulse DNA-based immunotherapy to treat solid tumors, which they are developing. The seven events in which they will be presenting include: PEGS: The Essential Protein Engineering Summit in Boston, MA, The 10th Annual EADO Congress: Advances in Diagnosis and Treatment of Skin Tumors in Vilnius, Lithuania, Boston Biotech: Cancer Advance NY in New York, New York, American Society of Gene and Cell Therapy (ASGCT) 17th Annual Meeting in Washington D.C., Marcum MicroCap Conference in New York, New York, American Cancer Society Blossom Ball in Sutter, CA, and The American Society of Clinical Oncology (ASCO) 50th Annual Meeting in Chicago, IL.
With three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma, OncoSec appears to have a grasp on the one thing everyone in the world is searching for: a cure or better treatment for cancer.
Abbatis Bioceuticals Corp.’s (OTCPINK: ATTBF) share volume continued to roar on May 1st with 516,896 shares exchanging hands. Recording a 16.67% gain, Abbatis Bioceutical Corp.’s share price closed at $1.05, up 15 cents from its previous close of $.90.
This share price increase comes at the heels of a recent press release from the company announcing it has acquired 34% interest in Instant Payment Systems LLC (IPS), a US entity based in Washington State through its wholly owned Washington subsidiary Abattis Bioceuticals International Inc.
Mike Withrow, CEO of Abattis stated, "This transaction enables the company to provide a valuable service and solves a problem to an unmet need for dispensaries of medical marijuana and other botanical medicines. The IPS cards and phone apps can be branded and loyalty programs can be used so the patients save money and can maintain a budget while managing their purchases of Medical Marijuana. The system also protects dispensaries from carrying cash as funds are automatically credited to their accounts. It is becoming clear that investors understand our comprehensive business model. We are not just about cultivation. We look forward to integrating this technology into our Washington State Lab model. We believe the use of this system by dispensaries will become the minimum standard requirement for dispensaries worldwide. We wished to thank the investment community for its support through our recent period of growth."
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a development stage biotechnology company focused on the discovery and development of drug and diagnostic product candidates to treat human diseases in the United States, announced the publication of positive independent peer-reviewed data on MANF in the areas of Alzheimer's disease and Diabetes, as well as additional studies further supporting its critical role in proper cellular function. The studies further corroborate the role of MANF's critical importance in reducing misfolded protein concentration and improving proper overall endoplasmic reticulum function.
In a study entitled "MANF Inhibits Tau Hyperphosphorylation in Cultured Neuronal Cells" published in the journal Chinese Pharmacological Bulletin, the authors demonstrated that MANF had a pronounced effect in reducing tau hyperphosphorylation, reducing cell death, and improving overall cellular health in a preclinical models. Misfolded tau is a significant part of the pathophysiology of Alzheimer's disease and Chronic Traumatic Encephalopathy (CTE).
On May 1st, the company’s share price closed at $.0713, up $.0043 (6.42%) from its previous closing price of $.067 on robust volume of 5,182,184
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.